Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR

Michael O'Dwyer

Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR

Michael O'Dwyer

Medicine

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Meeting
Volume	116
Publication status	Published - 1 Nov 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@misc{bb5c7e4540be4d04b74fe4a381028321,

title = "Nilotinib 300 Mg Twice Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia In Chronic Phase: Updated Results of the ICORG 0802 Phase 2 Study with Analysis of the GeneXpert System Versus IS BCR-ABL RQ PCR",

author = "Michael O'Dwyer",

year = "2010",

month = nov,

day = "1",

language = "English (Ireland)",

volume = "116",

type = "Other",

}